GE Healthcare Release: Head-To-Head Study Reports Patient Comfort With Visipaque (Iodixanol) And Isovue (Iopamidol) During Peripheral Arteriography

PRINCETON, N.J.--(BUSINESS WIRE)--GE Healthcare today announced results from a new study, which showed that patients receiving Visipaquetm (iodixanol) 320mg I/ml reported less discomfort, characterized by heat or cold sensation or pain upon injection, than patients receiving Isovue® (iopamidol) 370 mg I/ml during peripheral arteriography. As with other iodinated contrast agents, Visipaque is often associated with sensations of discomfort, warmth or pain. The data were presented at the American College of Cardiology’s 63rd Annual Scientific Session and Expo.1

Help employers find you! Check out all the jobs and post your resume.